Kevin Winthrop

2001–2025 年に発表

228
論文数
43,656
被引用数
100
h 指数
218
i10 指数

被引用数

Kevin Winthrop の年別被引用数2001 年: 被引用 1 件2002 年: 被引用 3 件2003 年: 被引用 12 件2004 年: 被引用 15 件2005 年: 被引用 11 件2006 年: 被引用 19 件2007 年: 被引用 32 件2008 年: 被引用 66 件2009 年: 被引用 92 件2010 年: 被引用 87 件2011 年: 被引用 109 件2012 年: 被引用 177 件2013 年: 被引用 224 件2014 年: 被引用 287 件2015 年: 被引用 322 件2016 年: 被引用 301 件2017 年: 被引用 374 件2018 年: 被引用 353 件2019 年: 被引用 1,321 件2020 年: 被引用 1,659 件2021 年: 被引用 1,742 件2022 年: 被引用 1,430 件2023 年: 被引用 1,072 件2024 年: 被引用 1,826 件2025 年: 被引用 852 件2026 年: 被引用 19 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,008 件、この内訳の 19.4%イギリス: 引用元論文 1,221 件、この内訳の 7.9%ドイツ: 引用元論文 833 件、この内訳の 5.4%中国: 引用元論文 830 件、この内訳の 5.3%イタリア: 引用元論文 828 件、この内訳の 5.3%フランス: 引用元論文 714 件、この内訳の 4.6%カナダ: 引用元論文 624 件、この内訳の 4%オランダ: 引用元論文 623 件、この内訳の 4%日本: 引用元論文 607 件、この内訳の 3.9%スペイン: 引用元論文 537 件、この内訳の 3.5%オーストラリア: 引用元論文 446 件、この内訳の 2.9%スイス: 引用元論文 362 件、この内訳の 2.3%
0%19.4%その他 31.5%

分野

  • Medicine81.8%
  • Immunology and Microbiology7.4%
  • Biochemistry, Genetics and Molecular Biology7.1%
  • Neuroscience0.6%
  • Pharmacology, Toxicology and Pharmaceutics0.5%
  • Health Professions0.5%
  • その他2.1%

トピック

  • Rheumatoid Arthritis Research and Therapies9.9%
  • Mycobacterium research and diagnosis6.4%
  • Tuberculosis Research and Epidemiology5.1%
  • Spondyloarthritis Studies and Treatments3.9%
  • Autoimmune and Inflammatory Disorders Research3.1%
  • Systemic Lupus Erythematosus Research2.8%
  • その他68.8%

共著者

全論文

検索で開く
  1. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Annamaria Iagnocco, Kim Lauper, Zhanguo Li, Iain B. McInnes, Eduardo Mysler, Peter Nash, Gyula Poór, Gorica Ristić, Felice Rivellese, Andrea Rubbert‐Roth, Hendrik Schulze‐Koops, Nikolay Stoilov, Anja Strangfeld, Annette H M van der Helm–van Mil, Elsa van Duuren, T. P. M. Vliet Vlieland, René Westhovens, Désirée van der Heijde - Annals of the Rheumatic Diseases 2022 被引用: 1,788

  2. An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases

    著者: , , , , , , , , , , , , , , , - American Journal of Respiratory and Critical Care Medicine 2007 被引用: 6,107

  3. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline

    著者: , , , , , , , , , , , , , , , , , , , , - Clinical Infectious Diseases 2020 被引用: 888

  4. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis

    著者: , , , , , , , , , , , , , - RMD Open 2023 被引用: 210

  5. The emerging safety profile of JAK inhibitors in rheumatic disease

    著者: - Nature Reviews Rheumatology 2017 被引用: 586

  6. Neutralizing monoclonal antibodies for treatment of COVID-19

    著者: , , , , , - Nature reviews. Immunology 2021 被引用: 794

  7. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Yoshiya Tanaka, Filip Van den Bosch, Annette H M van der Helm–van Mil, Alen Zabotti, Désirée van der Heijde, Josef S Smolen - Annals of the Rheumatic Diseases 2024 被引用: 331

  8. Adult Patients With Bronchiectasis

    著者: , , , , , , , , , , , , , , , , - CHEST Journal 2016 被引用: 430

  9. Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

    著者: , , , , , , , , , , , , , , , , - Annals of the Rheumatic Diseases 2022 被引用: 168

  10. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Eefje Jong, Joseph Keane, Wo-Jung Koh, Berit Lange, Sylvia Cardoso Leão, Rita Macedo, Turid Mannsåker, Theodore K. Marras, Jeannette Maugein, Heather Milburn, Tamas Mlinkó, Nora Morcillo, Kozo Morimoto, Dimitrios Papaventsis, Elia Palenque, Mar Paez-Peña, Claudio Piersimoni, Monika Polanová, Nalin Rastogi, Elvira Richter, María Jesús Ruiz‐Serrano, Anabela G. Silva, M. Pedro da Silva, Hülya Şimşek, Dick van Soolingen, Nóra Szabó, Rachel Thomson, Teresa Tórtola, Enrico Tortoli, Sarah Elizabeth Totten, Greg Tyrrell, Tuula Vasankari, Miguel Villar, Renata Walkiewicz, Kevin Winthrop, Dirk Wagner - European Respiratory Journal 2013 被引用: 858

  11. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme

    著者: , , , , , , , , , , - Annals of the Rheumatic Diseases 2020 被引用: 233

  12. A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus

    著者: , , , , , , , , , , , , , , - Arthritis & Rheumatology 2022 被引用: 152

  13. Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study

    著者: , , , , , , , , , , , , , , , , , , , , , , , - American Journal of Respiratory and Critical Care Medicine 2018 被引用: 343

  14. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Annals of the Rheumatic Diseases 2020 被引用: 288

  15. Oral surveillance and JAK inhibitor safety: the theory of relativity

    著者: , - Nature Reviews Rheumatology 2022 被引用: 196

  16. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database

    著者: , , , , , , , , , - Annals of the Rheumatic Diseases 2021 被引用: 160

  17. The role of IL-6 in host defence against infections: immunobiology and clinical implications

    著者: , , - Nature Reviews Rheumatology 2017 被引用: 424

  18. Incidence and Prevalence of Nontuberculous Mycobacterial Lung Disease in a Large U.S. Managed Care Health Plan, 2008–2015

    著者: , , , , , - Annals of the American Thoracic Society 2019 被引用: 333

  19. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

    著者: , , , , , , , , , , , , , , , , - Annals of the Rheumatic Diseases 2022 被引用: 139

  20. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme

    著者: , , , , , , , , , , , , , , - RMD Open 2020 被引用: 181

  21. 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kimberly S. Lakin, Alexandra Legge, Mindy S. Lo, Megan M. Lockwood, Rebecca E. Sadun, Namrata Singh, Nancy Sullivan, Herman Tam, Marat Turgunbaev, Amy S. Turner, James Reston - Arthritis & Rheumatology 2023 被引用: 195

  22. Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program

    著者: , , , , , , , , , , , , , - American Journal of Clinical Dermatology 2021 被引用: 139

  23. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Annals of the Rheumatic Diseases 2013 被引用: 858

  24. Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis

    著者: , , , , , , , , , , , , , , , , , , , - Annals of the Rheumatic Diseases 2016 被引用: 231